Research Summary

Analyzed using Evidence Intelligence™

AI Emulation Shows GLP-1 Improves HbA1c in Type 2 Diabetes

Last updated August 18, 2026

Key finding

GLP-1 reduced HbA1c by -1.21 mmol/mol (-0.11%); p < 0.001.

GLP-1 agonists' effect on HbA1c in adults with type 2 diabetes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

GLP-1 agonists' effect on HbA1c in adults with type 2 diabetes.

Clinical relevance

This study evaluated GLP-1 agonists' effect on HbA1c in adults with type 2 diabetes.

Keep in mind

Limitations were not clearly described in the extracted text.

Published in

Journal Reference

Publication details and source links for this paper.

Calum RM, Hristo P, Conor M, et al. Causal AI-Powered Emulation of Randomized Trials: A Case Study in Type 2 Diabetes. PLOS Digital Health. 2025;4(7):e0000927. doi:10.1371/journal.pdig.0000927

View DOI

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Basal insulin, Liraglutide and Body weight, HbA1c, Systolic blood pressure.

This study contributes evidence to

Intervention

Basal insulin

Outcome

Body weight

Evidence topic

HbA1c Reduction

Primary intervention

Basal insulin

Primary outcomes

Body weight
HbA1c
Systolic blood pressure

Evidence topics

HbA1c Reduction Weight Loss GLP-1 Receptor Agonists Insulin Therapies

Primary intervention

Basal insulin

Primary outcomes

Body weight HbA1c Systolic blood pressure

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 6 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

Insulin Therapies and HbA1c

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and HbA1c

Save evidence

Evidence relationship

GLP-1 Receptor Agonists and Body Weight

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Basal insulin → Body weight

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

HbA1c

Basal insulin → HbA1c

Evidence Intelligence™

EvidenceScore™: 79; Strong
ImpactScore™: 58; Slightly Positive
ConsistencyScore™: 67; generally_consistent

Based on 3 studies

Add to Evidence Tracker

Systolic blood pressure

Basal insulin → Systolic blood pressure

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Body weight

Liraglutide → Body weight

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 90; Very Positive
ConsistencyScore™: 100; consistent

Based on 5 studies

Add to Evidence Tracker

HbA1c

Liraglutide → HbA1c

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 100; consistent

Based on 3 studies

Add to Evidence Tracker

Systolic blood pressure

Liraglutide → Systolic blood pressure

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 2 studies

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 83; Strong
ImpactScore™: 90; Very Positive
ConsistencyScore™: 100; consistent

Based on 5 studies

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: Strong; Score 79 · Based on 3 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 100; consistent

Based on 3 studies

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Blood Pressure

Medications

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 2 studies

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

Body Weight Evidence Hub

All studies measuring Body Weight

5 studies

outcome_hub

Measures Body Weight as a key outcome.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

5 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

3 studies

outcome_hub

Measures HbA1c as a key outcome.

Blood Pressure Evidence Hub

All studies measuring Blood Pressure

2 studies

outcome_hub

Measures Blood Pressure as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Liraglutide and Body weight

Intervention: LiraglutideOutcome: Body weight

5 results

All studies on Liraglutide and HbA1c

Intervention: LiraglutideOutcome: HbA1c

3 results

All studies on Liraglutide

Intervention: Liraglutide

5 results

All studies measuring Body weight

Outcome: Body weight

5 results

All studies measuring HbA1c

Outcome: HbA1c

3 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Therapies improve HbA1c?

Strong Evidence

Insulin Therapies may improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.5 | weak positive | ConsistencyScore™ Generally Consistent | 1 study

Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists appears to improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.6 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 31 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve blood pressure?

Strong Evidence

GLP-1 Receptor Agonists may improve Blood Pressure.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Systolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence Hub Weight Loss Evidence Hub GLP-1 Receptor Agonists Evidence Hub Insulin Therapies Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Liraglutide and Body weight All studies on Liraglutide and HbA1c All studies on Basal insulin and HbA1c All studies on Liraglutide and Systolic blood pressure

Related research

Read related research summaries.

Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patients GLP-1RA improves metabolic outcomes in MASLD Liraglutide 3 mg pathway improves weight loss.Dietary interventions improve glycemic control in pre-diabetic patients

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.